Cutting-edge nanotechnology is now emerging, with strong clinical evidence, as an alternative to amorphous solid dispersion (ASD), able to not only address
bioavailability challenges but also deliver higher drug loads in much more patient friendly formats with fewer and smaller pills and easier regimens.